Home › Funds › Atle Fund Management AB › BBIO
Atle Fund Management AB position in BBIO
BRIDGEBIO PHARMA INC · Health Care
Atle Fund Management AB reported holding 163,697 shares of BBIO (BRIDGEBIO PHARMA INC) in its Q3 2026 13F filing — a position valued at US$10.8M, representing 2.88% of its reported portfolio and ranking #12 among its reported holdings. Atle Fund Management AB has disclosed BBIO holdings in 12 of the last 12 reported quarters, going back to Q4 2023.
Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR
How Atle Fund Management AB's BBIO position evolved
Atle Fund Management AB first disclosed a stake in BBIO in Q4 2023 at 23,985 shares (US$968K). The position peaked in Q1 2026 at 111,363 shares, worth US$11.9M. Across 12 filings, Atle Fund Management AB increased the stake 8 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 163,697 shares valued at US$10.8M — an increase of 38,990 shares quarter over quarter.. Notable position changes include a 58% increase in Q1 2024 (shares fell 18% over the following quarter), a 93% increase in Q4 2024 (shares rose 26% over the following quarter), a 47% increase in Q1 2025 (shares rose 25% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 23.98K | $968.27K | New |
| Q1 2024 | 37.84K | $1.17M | Add |
| Q2 2024 | 53.43K | $1.35M | Add |
| Q3 2024 | 53.43K | $1.36M | Hold |
| Q4 2024 | 103.03K | $2.81M | Add |
| Q1 2025 | 151.35K | $5.23M | Add |
| Q2 2025 | 165.48K | $7.15M | Add |
| Q3 2025 | 174.72K | $963.44K | Add |
| Q4 2025 | 141.30K | $10.81M | Reduce |
| Q1 2026 | 111.36K | $11.89M | Reduce |
| Q2 2026 | 124.71K | $9.29M | Add |
| Q3 2026 | 163.70K | $10.77M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BBIO and 13F data
BBIO (BRIDGEBIO PHARMA INC) is a Health Care company. 47 other funds we track also report a position in BBIO — the largest reported positions include Jupiter Topco LLC (US$1.05B), Janus Henderson Group (US$978.6M), Farallon Capital Management (US$800.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BBIO
- Jupiter Topco LLC 14.11M sh · $1.05B · Q2 2026
- Janus Henderson Group 13.18M sh · $978.61M · Q1 2026
- Farallon Capital Management 10.74M sh · $800.14M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 10.74M sh · $800.14M · Q2 2026
- Viking Global Investors 9.95M sh · $741.02M · Q2 2026
- VIKING GLOBAL INVESTORS LP 9.95M sh · $741.02M · Q2 2026
- Aisling Capital Management LP 4.59M sh · $341.83M · Q2 2026
- SC US (TTGP), LTD. 1.86M sh · $138.56M · Q2 2026
- STEELHEAD PARTNERS LLC 70.00M sh · $124.78M · Q2 2026
- CAPSTONE INVESTMENT ADVISORS, LLC 69.87M sh · $124.49M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.55M sh · $115.31M · Q2 2026
- FRONTIER CAPITAL MANAGEMENT CO LLC 1.37M sh · $102.27M · Q2 2026
More on Atle Fund Management AB
FAQ
How long has Atle Fund Management AB held BBIO?
Atle Fund Management AB has disclosed BBIO holdings in 12 of the last 12 reported quarters, going back to Q4 2023.
What is Atle Fund Management AB's current position in BBIO?
As of Q3 2026, Atle Fund Management AB holds 163.70K shares of BBIO (BRIDGEBIO PHARMA INC), valued at $10.77M, representing 2.88% of its reported portfolio and ranking #12.
Has Atle Fund Management AB been buying or selling BBIO?
In the latest 13F filing (Q3 2026), Atle Fund Management AB increased its position in BBIO. The position peaked in Q1 2026 at 111.36K shares.
Which other funds hold BBIO?
Other major institutional holders of BBIO include Jupiter Topco LLC, Janus Henderson Group, Farallon Capital Management, among 47 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.